|
Niox Group PLC shares were in the green on Tuesday, after it reported top and bottom-line growth for last year and a positive start to the current one. The Oxford, England-based medical device developer’s revenue increased 17% to £48.7 million in 2025 from £41.8 million in 2024. Clinical revenue rose 6.9% to £38.6 million, and Research revenue surged 77% to £10.1 million. Total sales of Niox’s FeNO asthma and chronic obstructive pulmonary disease tests increased 9.1% to 7.2 million, ‘indicating strong adoption and recurring usage.’ Pretax profit, meanwhile, increased 44% to £11.2 million from £7.8 million. Adjusted earnings before interest, tax, depreciation and amortisation climbed 21% to £16.7 million from £13.8 million, ‘reflecting strong operational leverage.’ Niox declared a final dividend of 1.55 pence per share, up 24% from 1.25p the year before. The company also highlighted its ‘strong balance sheet’, with cash totalling £19.9 million as of December 31 compared with £10.9 million one year prior. ‘I am pleased to report that 2025 has been another excellent year for Niox,’ commented Chair Ian Johnson. ‘The Clinical business continued to perform well driven by robust demand and the Research business saw a notable uplift in revenues, driven by a surge in clinical trials for COPD. ‘This is an exciting development for the company and a clear demonstration of the growing evidence for the use of FeNO beyond asthma.’ Looking ahead, Niox believes that trading ‘has started well’ in 2026 so far, adding: ‘The group has a robust strategy in place to expand the business and generate profitable growth. ‘The emerging evidence for the use of FeNO in COPD represents a large and exciting incremental future growth opportunity...we look forward to the future with confidence.’ Johnson continued: ‘With a strong financial position, expanding market opportunities, and continued innovation, Niox is well-positioned to deliver further shareholder value.’ Niox’s stock was 5.5% higher at 57.40p per share on Tuesday in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
